Codex DNA
| General Information | |
| Business: | We believe that we are a leading synthetic biology company focused on enabling researchers to rapidly, accurately and reproducibly build or “write” high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology enabled markets. Our synthetic biology solution addresses the bottlenecks across the multi-step process of building DNA and mRNA, as well as the significant limitations of existing solutions that prevent the rapid building of virtually error-free DNA and mRNA at a useable scale. A key part of our solution is our BioXp system, an end-to-end automated workstation that fits on the benchtop and is broadly accessible due to its ease-of-use and hands-free automation. |
| Industry: | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees: | 96 |
| Founded: | 2011 |
| Contact Information | |
| Address | 9535 Waples Street, Suite 100, San Diego, CA 92121-2993 |
| Phone Number | (858) 228-4115 |
| Web Address | http://www.codexdna.com/ |
| View Prospectus: | Codex DNA |
| Financial Information | |
| Market Cap | $423.45mil |
| Revenues | $7.9 mil (last 12 months) |
| Net Income | $-21.6 mil (last 12 months) |
| IPO Profile | |
| Symbol | DNAY |
| Exchange | NASDAQ |
| Shares (millions): | 6.7 |
| Price range | $16.00 - $16.00 |
| Est. $ Volume | $106.7 mil |
| Manager / Joint Managers | Jefferies/ Cowen and Company/ KeyBanc Capital Markets |
| CO-Managers | - |
| Expected To Trade: | 6/18/2021 |
| Status: | Priced |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |